aztreonam / Generic mfg. - LARVOL DELTA

Profile of Priority Antimicrobial-Resistant Pathogens and the Behavior of Multidrug-Resistant Tuberculosis in the Santiago de Cali District, Colombia. (PubMed, Pathogens) - "The expansion of resistance mechanisms suggests sustained selective pressure, underscoring the need for strategies to optimize antibiotics."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

SHORTEN-II: Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis. (clinicaltrialsregister.eu) - P4 | N=306 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open

ADJUNCTIVE HEMOPERFUSION USING HA-330 IN A SEVERE LUPUS FLARE WITH LUPUS NEPHRITIS AND DIFFUSE ALVEOLAR HEMORRHAGE: A CASE REPORT (ISN-WCN 2026) - "Proteinuria (UPCR 1.01 g/g) and imaging revealed bilateral infiltrates.She was clinically diagnosed with a severe SLE flare involving Class III lupus nephritis, diffuse alveolar hemorrhage, and acute renal failure, on top of relapsed pulmonary tuberculosis with superimposed hospital-acquired pneumonia.Initial therapy included high-flow oxygen, broad-spectrum antibiotics (Aztreonam + Cefepime, renally adjusted), anti-TB regimen excluding rifampicin, hydroxychloroquine, cautious corticosteroids (pulse withheld for ocular concern), and electrolyte correction.Results Due to worsening hypoxemia, rising inflammatory markers, and evolving kidney injury, two sessions of hemodialysis with hemoperfusion (HD + HP) using HA-330 were performed as cytokine-modulating adjunct therapy. Targeted cytokine removal may hasten stabilization and facilitate safer immunosuppression. The coexistence of DAH, lupus nephritis, infection, and relapsed TB underscores management challenges in..."

Case report • Clinical • Acute Kidney Injury • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

BEYOND CATHETERS: A MULTISOURCE MICROBIAL AND RESISTANCE LANDSCAPE AMONG DIALYSIS PATIENTS (ISN-WCN 2026) - "We observed very high resistance to 3rd-generation cephalosporins and fluoroquinolones (≈90–100%) but remained fully susceptible to carbapenems and amikacin in E. coli. While K. pneumoniae shows moderate–high resistance to ceftriaxone (58.3%) and aztreonam (66.7%), but lower aminoglycoside resistance (16.7%). Half of S. aureus was MRSA (oxacillin/cefoxitin 50%) with vancomycin still susceptible and low clindamycin(9.1%) and erythromycin(18.2%) resistance.Download: Download high-res image (252KB)Download: Download full-size imageIn exploratory modeling, organism type was the principal driver of resistance, though most organisms–antibiotic effects had wide confidence intervals. The most reliable association was lower tetracycline resistance in S. epidermidis (OR 0.012, 95% CI 0.0003–0.49; p=0.020)...Organism type showed significant relations to resistance rather than dialysis modality or specimen source. The importance of empirical therapy based on organisms are..."

Clinical • Chronic Kidney Disease • Infectious Disease • Nephrology • Pneumonia • Renal Disease

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. (PubMed, Antimicrob Agents Chemother) - "We performed a comprehensive clinical and genomic analysis of ceftazidime-avibactam-resistant Escherichia coli (CZA-R-Ec) collected at a tertiary cancer center (2017-2024) to identify patient- and isolate-level factors associated with reduced susceptibility to ATM/CZA and aztreonam-avibactam (AZA). In conclusion, CZA-R-Ec at our center are dominated by PBP3-insertion, blaNDM-5-positive lineages, for which ATM/CZA retains substantial in vitro activity and clinical efficacy. However, prior E. coli infection and blaCMY-42 variant positivity identify patients at risk for ATM/CZA non-susceptible infections."

Journal • Infectious Disease • Oncology

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. (PubMed, J Blood Med) - "Two allo-HSCT recipients whose febrile neutropenia persisted on empiric carbapenem were promptly escalated to imipenem/cilastatin/relebactam, alone or combined with aztreonam and tigecycline-before culture confirmation. Immediate empiric imipenem/cilastatin/relebactam for CRE-high-risk allo-HSCT recipients with febrile neutropenia rapidly controlled infections and permitted successful hematopoietic recovery. Prospective studies are warranted."

Journal • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation

High distribution of antibiotic residues in dairy milk and used testing methods in Indonesia - review. (PubMed, J Environ Sci Health B) - "The most common antibiotic residues found in field milk are Tetracycline, Penicillin, Erythromycin, Streptomycin, Chloramphenicol, Trimethoprim, and Aztreonam. The Kirby-Bauer Test, Mueller-Hinton Agar, California Mastitis Test, Methicillin-Resistant Staphylococcus Aureus, Mannitol Salt Agar, Oxacillin Resistance Screen Agar Base, and Polymerase Chain Reaction are the most commonly utilized methods for residue testing. These findings indicate the need to revise and expand national MRL coverage, strengthen tiered residue-testing strategies, and promote responsible antibiotic use to reduce the occurrence of residues and improve milk safety."

Journal • Review • Infectious Disease • Respiratory Diseases • Rheumatology

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Real-world use of ceftazidime/avibactam plus aztreonam in children with MBL-producing Gram-negative infections (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Real-world • Real-world evidence • Infectious Disease

Impact of ceftazidime/avibactam plus aztreonam on mortality in metallo-β-lactamase-producing Enterobacterales bloodstream infections: a propensity score-matched analysis (ESCMID Global 2026) - No abstract available

Infectious Disease

Outcomes of MBL-producing Pseudomonas aeruginosa vs Enterobacterales bloodstream infections treated with ceftazidime/avibactam plus aztreonam: a multi-centre study, Chile, 2019–2025 (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Comparison of ceftazidime plus avibactam and aztreonam synergy test from positive blood culture bottles with regular disk diffusion test with culture isolates (ESCMID Global 2026) - No abstract available

Aztreonam acts as a synergist for ceftazidime/avibactam against carbapenem-resistant Enterobacteriaceae (CRE) of various carbapenemase phenotypes in Southwestern China (ESCMID Global 2026) - No abstract available

Targeting metallo-β-lactamase endemicity: activity of novel meropenem-ANT3310 in combination with aztreonam against contemporary Enterobacterales (ESCMID Global 2026) - No abstract available

Combination therapy

Optimising synergy testing: a modified disc elution approach for aztreonam/ceftazidime/avibactam synergy testing in carbapenem-resistant Enterobacterales (ESCMID Global 2026) - No abstract available

Evaluation of ceftazidime/avibactam in combination with aztreonam, meropenem and amikacin in carbapenem-resistant Klebsiella pneumoniae strains and the distribution of carbapenemase-encoding genes (ESCMID Global 2026) - No abstract available

Combination therapy • Infectious Disease • Pneumonia

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: integral-1, a double-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Attenuation of ceftazidime/avibactam plus aztreonam but preservation of levofloxacin activity in Pseudomonas aeruginosa–Stenotrophomonas maltophilia co-culture models (ESCMID Global 2026) - No abstract available

Mechanism-based mathematical modelling describes aztreonam plus ciprofloxacin synergistic killing of resistant Pseudomonas aeruginosa strains with OprD deficiency and AmpC and efflux pump hyperproduction (ESCMID Global 2026) - No abstract available

Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections (ESCMID Global 2026) - No abstract available

Infectious Disease

Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease

Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials (ESCMID Global 2026) - No abstract available

Clinical • P3 data • PK/PD data

In vitro activity aztreonam and avibactam or ceftazidime/avibactam combinations against clinical Stenotrophomonas maltophilia isolates (ESCMID Global 2026) - No abstract available

Preclinical